RELVAR for COPD
Trial Summary
What is the purpose of this trial?
This study examines the effect of the ultra long acting beta agonist/corticosteroid bronchodilator combination fluticasone furoate/vilanterol trifenatate, on respiratory muscles and ventilation in adults with severe bronchitis or emphysema (COPD).
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop your current medications, but it requires participants to be on long-acting bronchodilator therapy. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug RELVAR for COPD?
Is RELVAR safe for humans?
How is the drug Fluticasone Furoate/Vilanterol unique for treating COPD?
Fluticasone Furoate/Vilanterol is unique because it combines a corticosteroid with a long-acting bronchodilator in a once-daily inhaler, which can improve lung function and reduce flare-ups more effectively than some other treatments. Its once-daily dosing may also help patients stick to their treatment plan better.13489
Research Team
Paul A Easton, MD, PhD
Principal Investigator
University of Calgary
Eligibility Criteria
This trial is for adults with severe COPD who can handle a minor surgery with sedation, take their meds regularly, and are able to walk. They should be on long-term bronchodilator therapy but not have had a major flare-up in the last 2 months or serious heart issues.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, using a standard dry powder inhaler
Follow-up
Participants are monitored for changes in minute ventilation, parasternal EMG, and pressure with phrenic stimulation after treatment
Treatment Details
Interventions
- Fluticasone Furoate
- Vilanterol Trifenatate
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor